Advanced Medical Isotope (OTCMKTS:RDGL) is a U.S.-based developer of proprietary technology for the production of alpha-emitting radioisotopes used in targeted cancer therapies. The company focuses on producing high-purity isotopes such as actinium-225 and astatine-211, which are critical components in next-generation radiopharmaceuticals. By leveraging innovative accelerator and separation techniques, Advanced Medical Isotope aims to supply reliable, scalable sources of rare isotopes that have historically been available only in limited quantities.
The company’s production platform integrates a customized cyclotron facility with specialized radiochemical processing to isolate and purify therapeutic radioisotopes. Advanced Medical Isotope offers contract manufacturing services to pharmaceutical and biotechnology firms developing targeted alpha therapies, including preclinical research supply and clinical-grade material for early-stage trials. Its technical capabilities encompass isotope irradiation, automated purification, quality control testing, and packaging in compliance with regulatory standards.
Since its incorporation in 2017, Advanced Medical Isotope has partnered with leading research institutions and contract research organizations across North America and Europe. The company is headquartered in the southeastern United States, with a production campus purpose-built to meet the stringent requirements of radiopharmaceutical manufacturing. Its executive team combines decades of experience in nuclear chemistry, medical physics, and pharmaceutical development, guiding strategic initiatives in scale-up and global distribution.
Looking ahead, Advanced Medical Isotope is focused on expanding capacity to meet growing demand for alpha-emitter supply as more oncology programs enter clinical development. The company is exploring collaborations with regional isotope producers and regulatory agencies to establish multiple production sites, ensuring uninterrupted supply chains for critical cancer therapies. With its end-to-end production model, Advanced Medical Isotope is positioning itself as a key enabler in the emerging field of targeted radiopharmaceuticals.
AI Generated. May Contain Errors.
Free RDGL Stock Alerts